ABBVIE INC (ABBV) Stock Overview
USA - NYSE:ABBV - US00287Y1091 - Common Stock
ABBV Key Statistics, Chart & Performance
The current stock price of ABBV is 225.65 USD. In the past month the price decreased by -1.73%. In the past year, price increased by 11.79%.
ABBV Latest News, Press Relases and Analysis
ABBV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| AMGN | AMGEN INC | 13.42 | 157.62B | ||
| GILD | GILEAD SCIENCES INC | 15.2 | 145.98B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.92 | 108.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.59 | 69.62B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.50B | ||
| ARGX | ARGENX SE - ADR | 90.19 | 51.14B | ||
| INSM | INSMED INC | N/A | 34.88B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.05 | 34.46B | ||
| NTRA | NATERA INC | N/A | 26.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.28B | ||
| BIIB | BIOGEN INC | 9.34 | 21.92B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.11 | 20.98B |
Related stock screener links
About ABBV
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS 60064 US
CEO: Richard A. Gonzalez
Employees: 55000
Phone: 18479327900
ABBVIE INC / ABBV FAQ
Can you describe the business of ABBVIE INC?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Can you provide the latest stock price for ABBVIE INC?
The current stock price of ABBV is 225.65 USD. The price decreased by -0.83% in the last trading session.
What is the dividend status of ABBVIE INC?
ABBVIE INC (ABBV) has a dividend yield of 2.87%. The yearly dividend amount is currently 6.24.
What is the ChartMill rating of ABBVIE INC stock?
ABBV has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Which stock exchange lists ABBV stock?
ABBV stock is listed on the New York Stock Exchange, Inc. exchange.
What do analysts say about ABBVIE INC (ABBV) stock?
37 analysts have analysed ABBV and the average price target is 232.38 USD. This implies a price increase of 2.98% is expected in the next year compared to the current price of 225.65.
Is ABBVIE INC (ABBV) expected to grow?
The Revenue of ABBVIE INC (ABBV) is expected to grow by 8.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
ABBV Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to ABBV. When comparing the yearly performance of all stocks, ABBV turns out to be only a medium performer in the overall market: it outperformed 69.73% of all stocks.
ABBV Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ABBV. While ABBV has a great profitability rating, there are quite some concerns on its financial health.
ABBV Financial Highlights
Over the last trailing twelve months ABBV reported a non-GAAP Earnings per Share(EPS) of 10.59. The EPS decreased by -1.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 6.38% | ||
| ROA | 2.71% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ABBV Forecast & Estimates
37 analysts have analysed ABBV and the average price target is 232.38 USD. This implies a price increase of 2.98% is expected in the next year compared to the current price of 225.65.
For the next year, analysts expect an EPS growth of 6.19% and a revenue growth 8.23% for ABBV